Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response

Phase 4 Unknown 100 enrolled Instituto de Investigación Hospital Universitario La Paz

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a low-intervention phase IV trial. The main objective is to optimize the treatment of patients with moderate-severe atopic dermatitis who require systemic treatment.

Timeline

Start: 2022-10-10
Primary completion: 2023-11
Completion: 2024-07

Publications

Marin-Candon A, Garcia-Garcia I, Arias P, Carcas AJ, Diaz-Garcia L, Feltes Ochoa R, Hernandez Cano N, Herranz Pinto P, Jimenez Gonzalez M, Lopez-Granados E, Martinez-Feito A, Mayor-Ibarguren A, Rosas-Alonso R, Seco-Meseguer E, Borobia AM. Identifying biomarkers of treatment response to ciclosporin in atopic dermatitis through multiomic predictive modelling: DERMATOMICS study protocol. BMJ Open. 2023 Jul 10;13(7):e072350. doi: 10.1136/bmjopen-2023-072350.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclosporine	Peptide	3 mg/kg	—

Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response

Summary

Timeline

Publications

Drugs

Indications